Found 238 results
Zhao L, Mao Z, Schneider LS, Brinton RD.  2011.  Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause.. Menopause. 18(10):1131-42.
Hamilton RT, Rettberg JR, Mao Z, To J, Zhao L, Appt SE, Register TC, Kaplan JR, Brinton RDiaz.  2011.  Hippocampal responsiveness to 17β-estradiol and equol after long-term ovariectomy: implication for a therapeutic window of opportunity.. Brain Res. 1379:11-22.
Sukhtankar D, Okun A, Chandramouli A, Nelson MA, Vanderah TW, Cress AE, Porreca F, King T.  2011.  Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain.. Mol Pain. 7:81.
Tumati S, Roeske WR, Largent-Milnes TM, Vanderah TW, Varga EV.  2011.  Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.. J Neurosci Methods. 199(1):62-8.
Irwin RW, Yao J, Ahmed SS, Hamilton RT, Cadenas E, Brinton RDiaz.  2011.  Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function.. Endocrinology. 152(2):556-67.
Wu T-W, Chen S, Brinton RD.  2011.  Membrane estrogen receptors mediate calcium signaling and MAP kinase activation in individual hippocampal neurons.. Brain Res. 1379:34-43.
Irwin RW, Wang JMing, Chen S, Brinton RDiaz.  2011.  Neuroregenerative mechanisms of allopregnanolone in Alzheimer's disease.. Front Endocrinol (Lausanne). 2:117.
Hanlon KE, Herman DS, Agnes RS, Largent-Milnes TM, Kumarasinghe IR, Ma SW, Guo W, Lee Y-S, Ossipov MH, Hruby VJ et al..  2011.  Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.. Brain Res. 1395:1-11.
North American Menopause Society.  2011.  The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010).. Menopause. 18(7):732-53.
Yao J, Rettberg JR, Klosinski LP, Cadenas E, Brinton RDiaz.  2011.  Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions.. Mol Aspects Med. 32(4-6):247-57.
Vardanyan R, Kumirov VK, Nichol GS, Davis P, Liktor-Busa E, Rankin D, Varga E, Vanderah T, Porreca F, Lai J et al..  2011.  Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.. Bioorg Med Chem. 19(20):6135-42.
Tarselli MA, Raehal KM, Brasher AK, Streicher JM, Groer CE, Cameron MD, Bohn LM, Micalizio GC.  2011.  Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain.. Nat Chem. 3(6):449-53.
Yao J, Brinton RDiaz.  2011.  Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.. Curr Pharm Des. 17(31):3474-9.
Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JMiguel, Mantyh PW, Vanderah TW.  2010.  A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.. Life Sci. 86(17-18):646-53.
Yao J, Hamilton RT, Cadenas E, Brinton RDiaz.  2010.  Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence.. Biochim Biophys Acta. 1800(10):1121-6.
Streicher JM, Ren S, Herschman H, Wang Y.  2010.  MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart.. Circ Res. 106(8):1434-43.
Henderson VW, Brinton RDiaz.  2010.  Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.. Prog Brain Res. 182:77-96.
Lochhead JJ, McCaffrey G, Quigley CE, Finch J, DeMarco KM, Nametz N, Davis TP.  2010.  Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation.. J Cereb Blood Flow Metab. 30(9):1625-36.
Papanicolaou KN, Streicher JM, Ishikawa T-O, Herschman H, Wang Y, Walsh K.  2010.  Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2.. J Mol Cell Cardiol. 49(2):196-209.
Largent-Milnes TM, Vanderah TW.  2010.  Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat. 20(3):291-305.
Largent-Milnes TM, Yamamoto T, Nair P, Moulton JW, Hruby VJ, Lai J, Porreca F, Vanderah TW.  2010.  Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.. Br J Pharmacol. 161(5):986-1001.
Tumati S, Roeske WR, Largent-Milnes T, Wang R, Vanderah TW, Varga EV.  2010.  Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA.. Br J Pharmacol. 161(1):51-64.